

29 May 2025

Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
Result of Annual General Meeting

Hemogenyx Pharmaceuticals plc is pleased to announce that, at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed by shareholders. The numbers of proxy votes for each resolution submitted prior to the meeting are presented below.

Proxy Voting Results

Ordinary Resolutions	Votes for	% of votes cast for	Votes Against	% of votes cast against	Total votes cast	Total votes cast as % of ISC (1)	Votes withheld (2)
1. To receive and adopt the Company's annual accounts for the financial year ended 31 December 2024 together with the directors' reports and auditor's report on those accounts	769,396	97.31	21,278	2.69	790,674	18.20	12,514
2. To approve the Directors' Remuneration Report	621,455	78.62	168,962	21.38	790,417	18.20	12,771
3. To authorise the re-appointment of Peter Redmond	601,846	75.44	195,969	24.56	797,815	18.37	5,373
4. To re-appoint PKF Littlejohn LLP as auditors	729,108	95.29	36,001	4.71	765,109	17.61	38,079
5. To authorise the Audit Committee to determine the level of the auditor's remuneration	647,389	85.67	108,250	14.33	755,639	17.40	47,549
6. To grant the Directors authority to allot and issue shares and grant rights to subscribe for shares in the Company for the purposes of Section 551 of the Act.	639,852	81.03	149,808	18.97	789,660	18.18	13,528
Special Resolutions	Votes for	% of votes cast for	Votes against	% of votes cast against	Total votes cast	Total votes cast as % of ISC (1)	Votes withheld (2)
7. To dis-apply the statutory rights of pre-emption in respect of the allotment of equity securities for cash under Section 561(1) of the Act.	638,646	80.88	151,014	19.12	789,660	18.18	13,528
8. To authorise the Directors to call a general meeting of the Company, other than an annual general meeting,	763,850	96.72	25,924	3.28	789,774	18.18	13,414

(1) The Company's issued share capital ("ISC") on 27 May 2025, being the date on which members had to be entered in the register of members of the Company in order to be entitled to attend and vote at the meeting, was 4,343,539 ordinary shares.

(2) A 'vote withheld' in respect of any resolution is not a vote in law and is not counted in the calculation of the proportion of the votes for and against it.

A copy of the resolutions passed has been submitted to the National Storage Mechanism and will shortly be available for inspection at <https://data.fca.org.uk/#/nsm/nationalstoragemechanism>

Enquiries:

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder
Peter Redmond, Director

headquarters@hemogenyx.com
peter.redmond@hemogenyx.com

SP Angel Corporate Finance LLP

Tel: +44 (0)20 3470 0470

Matthew Johnson, Vadim Alexandre, Adam Cowl

Peterhouse Capital Limited

Tel: +44 (0)20 7469 0930

Lucy Williams, Duncan Vasey, Charles Goodfellow

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.

The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rs@seg.com or visit www.rs.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RAGSELF DUEISESI